Stocktoria

NEXGEL, INC. NXGLW

Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
5/9
Piotroski F — financial health
-6.91
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$11.4M-$3.0M$4.5M-$1.4M$4.9M
2024$8.7M-$3.3M$2.7M-$4.3M$6.1M
2023$4.1M-$3.2M$374,000-$3.9M$5.2M
2022$2.0M-$4.7M$256,000-$3.1M$7.6M
2021$1.6M-$4.3M$8,000-$3.0M$12.1M
2020$674,000-$2.3M-$291,000-$2.1M$71,000

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Levy Adam R.Chief Executive Officer2026-06-23Sell5,000$0.59
Levy Adam R.Chief Executive Officer2026-06-18Sell6,000$0.59
Levy Adam R.Chief Executive Officer2026-06-11Sell3,000$0.61
Levy Adam R.Chief Executive Officer2026-06-08Sell3,000$0.55
Levy Adam R.Chief Executive Officer2026-06-04Sell3,000$0.59
Levy Adam R.Chief Executive Officer2026-06-01Sell2,000$0.59
Levy Adam R.Chief Executive Officer2026-05-29Sell3,000$0.60
Levy Adam R.Chief Executive Officer2026-05-28Sell7,000$0.61

Why these scores methodology →

Piotroski F-score: 5/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -6.91 (distress)

  • Working capital / assets 0.132
  • Retained earnings / assets -2.007
  • EBIT / assets -0.32
  • Equity / liabilities 0.878

Source: SEC EDGAR filings · CIK 0001468929 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.